Hepatocellular carcinoma: recurrence after liver transplantation and the primary cancer. Homo sapiens

Liver transplantation (LT) is an optimal treatment for a selected group of hepatocellular carcinoma (HCC) patients. However, about 10%-25% of LT cases develop post-transplant HCC recurrence, which drastically reduces the long-term survival of HCC patients. This study gives an analysis of the recurrent HCC after LT and the corresponding primary tumor. Results provide insight into the molecular mechanisms underlying post-LT HCC recurrence. Overall design: Recurrent HCC tissue vs. primary HCC tissue from the same patient. Biological replicates: 2 cases.

肝移植（Liver transplantation, LT）是针对经筛选的肝细胞癌（hepatocellular carcinoma, HCC）患者的最优治疗方案。然而，约10%~25%的肝移植病例会发生移植后肝细胞癌复发，该情况会显著降低肝细胞癌患者的长期生存率。本研究针对肝移植术后复发的肝细胞癌及其对应原发肿瘤开展分析，研究结果可为阐明移植后肝细胞癌复发的分子机制提供理论参考。
整体实验设计：同一患者来源的复发肝细胞癌组织与原发肝细胞癌组织对照。
生物学重复：2例样本。